Botulinum toxin type A for the treatment of sialorrhoea in XXXX : a clinical and neurophysiological study.

@entity1 @entity2133 @entity2708 @entity746
Botulinum toxin type A (BoNT/A) has been proposed as an alternative treatment for sialorrhoea in @entity1 with @entity746 ( @entity746 ). In an open-label prospective study, BoNT/A was injected into the parotid glands bilaterally using anatomic landmarks in 26 @entity746 @entity1 with bulbar symptoms. Two weeks after injection the severity of sialorrhoea and the related disability were evaluated subjectively and objectively. A group of healthy subjects acted as controls for saliva production. @entity1 also underwent electrophysiological tests to evaluate possible toxin effects in the nearby non-injected muscles by comparing the amplitude of compound motor action potentials (cMAPs) elicited by electrical stimulation and recorded from the orbicularis oculi and masseter muscles. After BoNT/A injections, of the 26 @entity1 treated, 23 reported that the severity of sialorrhoea improved and the disabling symptoms diminished. @entity2708 roll weight also decreased after BoNT/A injection, suggesting a reduction in saliva production. Two @entity1 complained of @entity2133 . BoNT/A injection left the cMAP amplitude unchanged, suggesting that botulinum toxin does not significantly affect the non-injected facial and masticatory muscles. In conclusion, intraparotid anatomically-guided BoNT/A injection is an effective, easy, and safe treatment for sialorrhoea in @entity1 with bulbar symptoms related to @entity746 .
